SDM101 utilizes Semaglutide, a GLP-1 receptor agonist that lowers blood sugar by stimulating insulin release from pancreatic beta cells and suppressing glucagon from alpha cells. The EndoEase™ platform transforms Semaglutide from an injectable to a sublingual form. This innovation extends painless treatment to conditions related to poor blood sugar control.
Improves compliance in diabetes patients
Expands medical access for obesity patients
Addresses the unmet medical needs of fatty liver disease patients
